Search

everythinglearnresearchcommunity

for

Search:↓

The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

Bexarotene gel shows promise as a new treatment for alopecia areata.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Topical ruxolitinib quickly improves non-segmental vitiligo.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.

Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.

Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.

Baricitinib is more effective than methotrexate for severe alopecia areata.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

A special gel with medicine helps prevent melanoma from coming back after surgery.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Adalimumab helped control a child's severe eye disease when other treatments failed.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.